Noopept

Technically a dipeptide-derived synthetic nootropic rather than a traditional peptide. Noopept (INN: Omberacetam) is N-phenylacetyl-L-prolylglycine ethyl ester, a small molecule built on a Pro-Gly dipeptide backbone with a phenylacetyl cap and ethyl ester modification. It functions as a prodrug of the endogenous neuropeptide cycloprolylglycine (cPG), which is also a natural metabolite of IGF-1.

Developed at the Zakusov Research Institute of Pharmacology (Russian Academy of Medical Sciences) by T.A. Gudasheva in 1996. Approved and sold over-the-counter in Russia for impaired memory, attention, and cognitive function. Not approved in the US, Canada, or the EU. Studied in one published open-label comparative clinical trial (n=53) and extensive preclinical research, predominantly from the originating laboratory.

Noopept has been studied in one published open-label comparative trial (Neznamov & Teleshova, 2009, n=53) showing MMSE improvement from 26 to 29 over 56 days at 20 mg/day — but the trial was not placebo-controlled, not blinded, and conducted at a single center. Preclinically, Noopept is reported as approximately 1,000x more potent than piracetam by weight.

Ostrovskaya et al. (2008) demonstrated increased BDNF and NGF expression in rat hippocampus after chronic administration. Pelsman et al. (2003) showed neuroprotection against oxidative damage in human cortical neurons (including Down syndrome neurons). The compound operates through multiple mechanisms including AMPA receptor modulation (via cPG metabolite), neurotrophin upregulation, α7 nicotinic receptor involvement, antioxidant activity, and HIF-1 activation.

The Alzheimer's Drug Discovery Foundation has noted that most research originates from a single laboratory group, which is a significant limitation for evidence confidence.